Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis.

This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.

All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.

Inclusion Criteria:

1.Patient treated by everolimus-eluting SYNERGY® stent

Exclusion Criteria:

1. Patient or legal guardian won't give consent to use collected data

All consecutive patients treated with SYNERGY stents at Bern and Fribourg university hospitals and La Tour Hospital in Geneva until June 30, 2014 will be retrospectively included in the study.